Hepatitis C Drug

What many people don't realise is that hepatitis infections can quietly damage the liver over time, leading to serious conditions, including cirrhosis and eventually, hepatocellular carcinoma (HCC), the most common type of liver cancer.

A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said.

Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.

World drug abuse day 2020: Around 35.6 million people across the world are victims of drug abuse according to the World Drug Report 2020, which is published by the United Nations Office on Drugs and Crime. Young adults and teenagers account for the largest share of those using drugs and most of them suffer from HIV, Hepatitis C and other related di...

Several drugs approved for the treatment of hepatitis C viral infection have been identified as potential candidates against COVID-19 caused by the SARS-CoV-2 coronavirus, according to a study based on extensive calculations using supercomputer simulations.

World Hepatitis Day: Hepatitis is essentially inflammation of the liver. It is most commonly caused by hepatitis virus. However, other toxic substances like alcohol, certain medications and drugs can also lead to hepatitis.

Amritsar, Punjab: In Amritsar’s Ajnala town, close to Pakistan’s border, 23-year-old Pooja (name changed), has been coping with her husband Parambir’s drug addiction for over five years. “After every treatment session, he promises to quit. But a few days after we are back home, he is back to the habit,” she says, despair and worry written...

It's estimated that over 70 million people around the world have chronic Hepatitis C infection and nearly 400,000 people die each year from Hepatitis C-related liver diseases. Ahead of World Hepatitis Day the drug has now been launched to treat it.

Boston: Hepatitis C virus drugs available in India not only increase life expectancy but also reduce lifetime health care costs by over USD 1,300 per person. Researchers found that the generic directly-acting antiviral (DAA) treatments available in India are cost effective. “More than 9 million people are infected with Hepatitis C virus (HCV) in ...

Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.

Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb's daclatasvir tablets used in the treatment of Hepatitis C.

A latest breakthrough treatment for the deadly Hepatitis C virus could soon be available in India as 11 Indian firms have been given licenses by its American manufacturer following an approval from US authorities.

Last month, NPPA had fixed the ceiling price of as many as 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, Hepatitis C and diabetes.

With the NPPA's move, some of the key drugs such as Tenofovir, Lamivudine, Raltegravir used for treatment of HIV/AIDS and Sofosbuvir, which is used against Hepatitis C will become cheaper.

Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C.

What many people don't realise is that hepatitis infections can quietly damage the liver over time, leading to serious conditions, including cirrhosis and eventually, hepatocellular carcinoma (HCC), the most common type of liver cancer.

A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said.

Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.

World drug abuse day 2020: Around 35.6 million people across the world are victims of drug abuse according to the World Drug Report 2020, which is published by the United Nations Office on Drugs and Crime. Young adults and teenagers account for the largest share of those using drugs and most of them suffer from HIV, Hepatitis C and other related di...

Several drugs approved for the treatment of hepatitis C viral infection have been identified as potential candidates against COVID-19 caused by the SARS-CoV-2 coronavirus, according to a study based on extensive calculations using supercomputer simulations.

World Hepatitis Day: Hepatitis is essentially inflammation of the liver. It is most commonly caused by hepatitis virus. However, other toxic substances like alcohol, certain medications and drugs can also lead to hepatitis.

Amritsar, Punjab: In Amritsar’s Ajnala town, close to Pakistan’s border, 23-year-old Pooja (name changed), has been coping with her husband Parambir’s drug addiction for over five years. “After every treatment session, he promises to quit. But a few days after we are back home, he is back to the habit,” she says, despair and worry written...

It's estimated that over 70 million people around the world have chronic Hepatitis C infection and nearly 400,000 people die each year from Hepatitis C-related liver diseases. Ahead of World Hepatitis Day the drug has now been launched to treat it.

Boston: Hepatitis C virus drugs available in India not only increase life expectancy but also reduce lifetime health care costs by over USD 1,300 per person. Researchers found that the generic directly-acting antiviral (DAA) treatments available in India are cost effective. “More than 9 million people are infected with Hepatitis C virus (HCV) in ...

Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.

Drug firm Zydus Cadila has inked a generic manufacturing pact with the Medicines Patent Pool for manufacturing global pharma major Bristol-Myers Squibb's daclatasvir tablets used in the treatment of Hepatitis C.

A latest breakthrough treatment for the deadly Hepatitis C virus could soon be available in India as 11 Indian firms have been given licenses by its American manufacturer following an approval from US authorities.

Last month, NPPA had fixed the ceiling price of as many as 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, Hepatitis C and diabetes.

With the NPPA's move, some of the key drugs such as Tenofovir, Lamivudine, Raltegravir used for treatment of HIV/AIDS and Sofosbuvir, which is used against Hepatitis C will become cheaper.

Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C.